Last month Pfizer and the Broad Institute published details of their work to find diabetes drug targets in genome data. Now Pfizer has teamed with Merck KGaA to give the institute another pot of cash to investigate lupus.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
Clinical trials have increased in complexity over the past decade, with sponsors working with an increasing number of sites, countries and service providers. These massive globalized studies place new strains on the organization of essential study documents, collectively known as the trial master file (TMF). In response, vendors have pushed a technological solution: electronic TMF systems.
Vendors pitch eTMFs as a way to easily and securely share clinical study documents with internal and external teams, while also realizing many of the benefits electronic systems have over paper-based processes. Whereas paper files can be lost or destroyed and are only accessible where they are physically located, documents stored in an eTMF are less vulnerable to physical damage and can be viewed from anyplace with access to the web.
POPULAR COMMENT THREADS
It is almost four years since Facebook passed 500 million users. And while the role of it and other social media in clinical trials has generated lots of media coverage and conference chatter, the industry is yet to fully embrace the tools. Survey data published this week show just how there is to go.
British government funding groups are looking for startups that will sustain the resurgence in the country's economy. And that means more money for bioinformatics businesses, with the Technology Strategy Board accepting applications for new funding from next month.
Every clinical trial has its outliers. Some patients respond far better to the treatment than the rest, but the focus on efficacy across the study population means these results--and their implications--are lost in the shuffle. The National Cancer Institute is trying to change this by improving the tracking of data on these "exceptional responders."
While it is years now since clinical trial participants started talking about their experiences online, the industry is still searching for the best way to approach the phenomenon. And with pharma needing to improve the clinical trial process, the onus is on the industry to find systems that not only manage the negative implications of social media, but tap into its power, too.
The parents of a teenage boy who died of glioblastoma multiforme are trying to build a database of 50,000 human genomes.
The Open Source Drug Discovery program India set up in 2008 promised to disrupt the current model and deliver new treatments for neglected diseases. Six years later, OSDD is still working towards these goals, but has run up against shortages in two age-old areas: Money and skills.
From Our Sister Sites
Dr. John Porter, formerly the U.K. medical team lead for Pfizer, will become Novartis' medical affairs director for Northern Europe.
Whooping cough is back with a vengeance, and the culprit may be the changing nature of the bacterium that causes the highly infectious disease.